Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Propofol sedation versus placebo during LISA in very preterm infants with respiratory distress syndrome
2024-518836-36-00Phase 3Authorised
- Sponsor
- CHU Grenoble Alpes
- Start
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in respiratory distress syndrome (RDS) comparing Propofol sedation during LISA with Placebo during LISA (2 arms). Primary endpoint: Rate of mechanical ventilation up to 72 hours of life. Planned start Oct 2019; status: authorised.
02
Drugs
propofol
03
Conditions
respiratory distress syndrome (RDS)
Beyond the preview
Go deeper on 2024-518836-36-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518836-36-00.